부산대학교 도서관

Docetaxel and paclitaxel both belong to the taxane family and block depolymerization of tubulin. In ovarian carcinoma, the development of docetaxel has followed a rational path over the last 10 years. Here, we review data from Phase I and II studies that have established docetaxel-platinum compound combinations as valuable options in the treatment of ovarian cancer. A large international Phase III study has proved that the docetaxel-carboplatin combination is at least equivalent to the standard paclitaxel-carboplatin regimen in the first-line setting for stage III-IV ovarian carcinomas.
Author(s): Paul H Cottu [sup.[[dagger]]] [sup.1] , Laurent Mignot [sup.2] , Véronique Diéras [sup.3] Keywords : docetaxel; ovarian cancer Ovarian cancer remains the leading cause of death from gynecological cancer [...]